News | Drug-Eluting Balloons | September 18, 2017

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon

Trial includes 328 peripheral arterial disease patients from 18 centers across Germany and Austria

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon

September 18, 2017 — Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics' Stellarex .035-inch drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne Brodmann, M.D., of the Medical University of Graz in Austria, presented the data as a late-breaking trial at the Vascular Interventional Advances (VIVA 17) Annual Conference, Sept. 11-14 in Las Vegas.

The ILLUMENATE EU RCT, which is part of a series of five clinical trials evaluating the safety and efficacy of Stellarex for superficial femoral artery and popliteal disease, includes 328 PAD patients from 18 centers across Germany and Austria and compares the Stellarex DCB to an uncoated angioplasty balloon. The results show that at 24 months, 75.9 percent of patients treated with Stellarex maintained blood flow through the treated segment of the diseased artery, assessed through blinded core-lab adjudicated patency. Only 61 percent of patients treated with an uncoated balloon still maintained blood flow at 24 months. The data shows that Stellarex demonstrates higher efficacy and patency results, and longer treatment durability compared to an uncoated balloon, which is the current standard of care in the United States.

"The Stellarex DCB produced durable results in this rigorous trial, validating earlier findings among the ILLUMENATE trial series," stated Brodmann. "These consistent, top-tier outcomes are achieved with a low-dose balloon.  Stellarex is the first low-dose DCB to demonstrate a significant treatment effect at two years." Low-dose DCBs are those that deliver a dose of only 2 micrograms of the drug paclitaxel per square millimeter, which is lower than some other DCBs on the market, according to Philips.

The ILLUMENATE EU RCT has independent evaluation including supervision by a clinical events committee, a data safety and monitoring board, and assessment by angiographic and duplex ultrasound core laboratories. Philips Spectranetics fully funded the ILLUMENATE EU RCT as part of the ILLUMENATE series of five trials to evaluate the benefits of Stellarex .035-inch for various patient groups in comparison to an uncoated percutaneous transluminal angioplasty (PTA) balloon, which is the current endovascular standard of care.

The Stellarex drug-coated balloon is designed to restore and maintain blood flow to arteries in patients with peripheral arterial disease. Spectranetics launched the device in Europe in January 2015 and received U.S. Food and Drug Administration (FDA) approval in the U.S. in July 2017. Philips acquired Spectranetics in August 2017.

For more information: www.usa.philips.com/healthcare

Read about other Late-breaking Trial Presentations at ESC 2017.

Related Content

MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
Overlay Init